Search

We Need Your Feedback!

Tell us what you think about our latest design changes, as well as any bugs, problems or suggestions you may have that would improve your user experience.

  • myRisk App
  • Myriad Publications
  • Documents and Forms
  • Login
  • |
  • Register
MyriadPro

Extensive information for Myriad's Healthcare Professionals.

Toggle menu

Skip to content
  • Specialties
    • Genetics
    • OB/GYN & Primary Care
    • Oncology & Surgery
    • Urology
    • Gastroenterology
    • Other Specialties
  • Products
  • Genes, Cancers, & Syndromes
  • MyriadPro Account
    • Login / Register
    • What is a MyriadPro Account?
    • MyriadPro Account FAQ
  • Request Supplies
    • Test Kits
    • Patient Materials

Posts classified under: Genetic Counselor

MyriadPro  ⁄  Genetic Counselor
9Jan2018

riskScore Validations Study

January 9, 2018

Myriad was excited to present the validation study for riskScoreTM at this year’s annual San Antonio Breast Cancer Symposium, which showed riskScore’s great clinical value.

As you know, riskScore is a clinically validated risk model that can help provide a personalized risk of breast cancer for eligible patients*. The model does this by assessing over 80 Single Nucleotide Polymorphisms (SNPs) known to be associated with breast cancer, combined with the Tyrer-Cuzick** model.

Summary of the validation study

1. The remaining lifetime and 5-year breast cancer risk estimates determined by riskScore were highly significant

2. riskScore added significant breast cancer risk discrimination independent of that captured by Tyrer-Cuzick for both remaining lifetime risk and 5-year risk


Resources to help you review and understand this data

1. Webinar with the lead author, Elisha Hughes, PhD, walking through the methodology and results in detail: https://vimeo.com/247363805

2. The poster presentation from the San Antonio Breast Cancer Symposium:https://myriad-web.s3.amazonaws.com/publications/45923666-SABCS%202017%20Hughes_Presented%20on%20December%206,%202017.pdf

3. Your local Myriad Account Executive and Regional Medical Specialist

4. Myriad’s Medical Services Department: 800-469-7423 ext. 3850 or emailinghelpmed@myriad.com

Click Here to Access Myriad Pro
 

 

*Eligible patients are women of solely European ancestry who have no history of breast disease or a known familial mutation in a gene associated with breast cancer

**Reference: Tyrer J, et al. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004 23:1111-30.

16Feb2016

How is homologous recombination deficiency (HRD) identified?

February 16, 2016

Homologous recombination deficiency (HRD) is a cellular weakness resulting from the disruption of a major DNA repair pathway. HRD status can be identified by tumor testing.  Because the homologous recombination (HR) pathway can be disrupted by many mechanisms beyond just genetic mutations, relying solely on gene sequencing may miss tumors with other causes of HRD, both known (such as promoter methylation) and unknown.

Relying solely on gene sequencing may miss tumors with other causes of HRD

Untitled-1-1.jpg

 

Myriad’s newest companion diagnostic, myChoiceTM HRD, is an algorithmic measurement of three biomarkers associated with homologous recombination deficiency, combined with next-generation sequencing of the BRCA1 and BRCA2 genes in the tumor.  The three biomarkers, loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST), have all been individually shown to be associated with BRCA1/2 deficiency.1

Content Divider

HRD2.png

However, when combined, the three biomarkers produce a more robust, discriminating measurement of HRD than any of the individual biomarkers alone.1

Read the full analytical validation study for myChoice HRD here.

 HRD3.png

myChoice HRD is Myriad’s newest companion diagnostic that is helping advance the science of precision medicine for patients with many different types of cancer.3 

Learn more about myChoice HRD here


 References:

 

  • 1. Timms KM et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.  Breast Cancer Research (2014).  16:475.
  • 2. Timms KM et al. DNA repair deficiencies in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA study.  Presented at ESMO 2015 Congress.
  • 3. myChoice HRD CDx is considered investigational and has not been reviewed or approved by the FDA.
26Jan2016

New Data Shared at AACR-IASLC

January 26, 2016

New Data Shared at AACR-IASLC

As part of Myriad’s ongoing commitment to advance the science of lung cancer care, we shared exciting new data at this year’s AACR-IASLC International Joint Conference in San Diego. Here is a quick recap of the poster presentation targeted at improving patient outcomes in early stage lung cancer.

lung-1.jpg

Background:

Recurrence and lung cancer mortality in resected, early stage non-small cell lung cancer (NSCLC) are likely due to the presence of micro-metastatic disease not detected during surgery or the pre-surgical assessment. The aim of this study was to validate cell cycle progression gene expression (CCP Score) and the molecular Prognostic Score as predictors of 5-year distant recurrence-free survival in a cohort of surgically treated lung adenocarcinomas without adjuvant treatment.

Content Divider

Conclusions:

  • The CCP score and the molecular prognostic score are independent prognostic markers of 5-year distant recurrence in patients with early stage lung adenocarcinoma treated with surgery, independent of age, tumor size and pleural invasion.
  • The prediction of risk of distant recurrence in resected lung adenocarcinoma patients can be improved over that obtained by the current standard of pathological stage by incorporating tumor expression of proliferation markers (CCP score).
  • Improved risk stratification can help identify patients in need of additional treatment and prioritize patients for trials of emerging new therapies.

Click here to view the full version of this poster

For more information on how myPlan Lung Cancer incorporates tumor aggressiveness and pathological stage to provide an accurate and objective measure of patient mortality risk, please visit

myPlanlungcancer.com

human

Myriad myRisk App

Find clinical information associated with Myriad’s myRisk cancer test.

love

Myriad Promise

Myriad promises to provide affordable access to testing.

star

Hereditary Cancer Quiz

Identify appropriate patients for hereditary cancer testing before or during your patient’s appointment.

convert

Patient Education Videos

Guide your discussions with patients on hereditary cancer syndromes.

  • Contact Us
  • Terms of Use
  • Glossary
  • References
  • Myriad Certifications
  • Privacy Policy
  • Speaker Connect
Copyright © 2016 Myriad Genetic Laboratories all rights reserved.
Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.